投资者

/投资者
投资者 2018-05-30T18:41:16+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

3.24
0.00 (0.00%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :0
Date :08-22-2019

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at World Diabetes Congress

七月 10th, 2019|Oramed to Present at World Diabetes Congress已关闭评论

NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific [...]

Oramed Announces Xiaoming Gao Joins Board of Directors

七月 2nd, 2019|Oramed Announces Xiaoming Gao Joins Board of Directors已关闭评论

Chairman of HTIT has decades of experience in the diabetes sector in China NEW YORK, July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral [...]

Oramed Provides Clinical Update with Meaningful Data Expected by Year-End

六月 18th, 2019|Oramed Provides Clinical Update with Meaningful Data Expected by Year-End已关闭评论

Completed recruitment and randomization of all patients in the primary cohort of Phase IIb HbA1c trial for oral insulin capsule ORMD-0801, potentially the first commercial oral insulin capsule for the treatment of Type 2 diabetes; [...]

Oramed to Present at BIO International Convention

六月 3rd, 2019|Oramed to Present at BIO International Convention已关闭评论

NEW YORK, June 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Mark Hasleton, Vice President Business [...]